PT - JOURNAL ARTICLE AU - Carvalho, Nuno R. G. AU - He, Yixuan AU - Smadbeck, Patrick AU - Flannick, Jason AU - Mercader, Josep M. AU - Udler, Miriam AU - Manrai, Arjun K AU - Moreno, Jordi AU - Patel, Chirag J. TI - Assessing the genetic contribution of cumulative behavioral factors associated with longitudinal type 2 diabetes risk highlights adiposity and the brain-metabolic axis AID - 10.1101/2024.01.30.24302019 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.30.24302019 4099 - http://medrxiv.org/content/early/2024/01/31/2024.01.30.24302019.short 4100 - http://medrxiv.org/content/early/2024/01/31/2024.01.30.24302019.full AB - While genetic factors, behavior, and environmental exposures form a complex web of interrelated associations in type 2 diabetes (T2D), their interaction is poorly understood. Here, using data from ∼500K participants of the UK Biobank, we identify the genetic determinants of a “polyexposure risk score” (PXS) a new risk factor that consists of an accumulation of 25 associated individual-level behaviors and environmental risk factors that predict longitudinal T2D incidence. PXS-T2D had a non-zero heritability (h2 = 0.18) extensive shared genetic architecture with established clinical and biological determinants of T2D, most prominently with body mass index (genetic correlation [rg] = 0.57) and Homeostatic Model Assessment for Insulin Resistance (rg = 0.51). Genetic loci associated with PXS-T2D were enriched for expression in the brain. Biobank scale data with genetic information illuminates how complex and cumulative exposures and behaviors as a whole impact T2D risk but whose biology have been elusive in genome-wide studies of T2D.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by NIEHS R01 ESS032470 and NIA RF1AG074372.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Harvard University IRB approved of this study (IRB: IRB16-245).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll code and methods for reproducing the results of this paper is publicly available on our github repository. We deposit the PXS-T2D summary statistics in FigShare (doi: 10.6084/m9.figshare.24975564).